EYPT news

EyePoint announced a strategic reduction of its workforce by over half and a pause of wet AMD trials following a failed Phase 3 study for DURAVYU, shifting focus to its DME program to conserve $30 million in annual cash.

Topline results from the LUCIA phase 3 trial for DURAVYU failed to meet the primary endpoint for statistical non-inferiority, while demonstrating a successful safety profile and a 38% reduction in injections.

EyePoint expanded analysis of its LUGANO Phase 3 trial for DURAVYU in wet AMD, citing potential practice-changing data and renewed confidence just months before an anticipated FDA filing in 2027.

EyePoint reported mixed results from its LUGANO Phase 3 trial for wet AMD drug DURAVYU, missing the primary endpoint due to a small patient cohort but excelling in key secondary metrics. The company expects data from a second trial in late 2026.

EyePoint Inc. has completed enrollment for its pivotal DURAVYU trials for diabetic macular edema, achieved in just five months with 480 patients. Topline data is anticipated in 4Q 2027, followed by FDA and EMA review.

EyePoint Inc. agreed to settle a lawsuit brought by the US government related to kickbacks for its drug DEXYCU. This legal resolution mitigates potential liability but signals significant regulatory scrutiny for the company.

EyePoint's board approved Amendment No. 3 to its 2023 Long-Term Incentive Plan, increasing the maximum shares available for equity awards to 15.3 million, pending stockholder approval. The expansion provides additional capacity for employee compensation and retention through equity-based awards.